Clinical trial
The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)
NCT00396006 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)
- Lead sponsor
- Baxalta now part of Shire
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 27, 2006
- Completion date
- December 14, 2007
- Enrollment
- 21 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.